Cargando…
Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer
BACKGROUND: There are many molecular differences between estrogen receptor α (ERα)-positive and ER-negative breast cancers. Recent analyses have shown that the former can be divided into two subtypes, luminal A and luminal B. These differ in response to endocrine therapy and chemotherapy, and in pro...
Autores principales: | Endo, Yumi, Yamashita, Hiroko, Takahashi, Satoru, Sato, Shinya, Yoshimoto, Nobuyasu, Asano, Tomoko, Hato, Yukari, Dong, Yu, Fujii, Yoshitaka, Toyama, Tatsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364092/ https://www.ncbi.nlm.nih.gov/pubmed/25528056 http://dx.doi.org/10.1186/1471-2407-14-990 |
Ejemplares similares
-
Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N‐Acetyltransferase NAT2
por: Conway, Louis P., et al.
Publicado: (2020) -
Human Arylamine N-Acetyltransferase 1 (NAT1) Knockout in MDA-MB-231 Breast Cancer Cell Lines Leads to Transcription of NAT2
por: Carlisle, Samantha M., et al.
Publicado: (2022) -
Arylamine N-Acetyltransferases in Mycobacteria
por: Sim, Edith, et al.
Publicado: (2008) -
Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey
por: Sabbagh, Audrey, et al.
Publicado: (2011) -
Myoepithelial Carcinoma of the Breast Treated with Surgery and Chemotherapy
por: Endo, Yumi, et al.
Publicado: (2013)